GlaxoSmithKline Purchases Illumina, Inc.'s HumanHap550 BeadChips For Large-Scale Whole-Genome Association Studies
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) announced today that it entered into a multi-million dollar agreement with GlaxoSmithKline (GSK) for the purchase of 1,000 HumanHap550 BeadChips to be run at an undisclosed third-party facility and the addition of a statement of work to utilize Illumina’s Fast-Track Genotyping Service to process approximately 4,000 disease samples for pharmacogenetics application. By the end of 2006, Illumina will have genotyped more than 15,000 samples and reported nearly 3.5 billion genotypes to GSK.